A short review on antibody therapy for COVID-19

G Venkat Kumar; V Jeyanthi; S Ramakrishnan

doi:10.1016/j.nmni.2020.100682

A short review on antibody therapy for COVID-19

New Microbes New Infect. 2020 Apr 20:35:100682. doi: 10.1016/j.nmni.2020.100682. eCollection 2020 May.

Authors

G Venkat Kumar¹, V Jeyanthi², S Ramakrishnan³

Affiliations

¹ Department of Biotechnology, Ponnaiyah Ramajayam Institute of Science and Technology, Thanjavur, 613403, Tamil Nadu, India.
² Department of Biotechnology, SRM Arts and Science College, Kattankulathur, Chengalpattu District, 603203, Tamil Nadu, India.
³ Structural Biophysics Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.

Abstract

The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.

Keywords: Convalescent plasma therapy; SARS-CoV-2; monoclonal antibody therapy; receptor binding domain; spike protein.

Publication types

Review